{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Neurocrine Biosciences, Inc.
Neurocrine Biosciences Experiences Evaluation Revision Amid Mixed Market Performance Indicators
Neurocrine Biosciences, Inc. has recently revised its evaluation amid changing market conditions. The company's stock price is currently $129.64, reflecting a year-to-date return of 13.87%, which is below the S&P 500's 18.89%. Technical indicators present a mixed outlook, with varying trends across different time frames.
Neurocrine Biosciences Forms Death Cross, Signaling Potential Bearish Trend
Neurocrine Biosciences, Inc. has recently encountered a Death Cross, indicating a potential shift in market sentiment. Technical indicators present a mixed outlook, with a bearish weekly MACD and a bullish monthly perspective. Year-to-date, the stock has declined 6.66%, underperforming the S&P 500's modest gain.
Neurocrine Biosciences Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics
Neurocrine Biosciences, Inc. has adjusted its valuation, showcasing a P/E ratio of 36 and a price-to-book value of 5.20. With strong operational efficiency reflected in a ROCE of 28.21% and a one-year return of 13.16%, the company maintains a competitive edge in the Pharmaceuticals & Biotechnology sector.
Is Neurocrine Biosciences, Inc. overvalued or undervalued?
As of November 21, 2025, Neurocrine Biosciences, Inc. has an attractive valuation grade, indicating it is undervalued with a favorable P/E ratio of 35 and strong ROCE of 30.61%, although it has underperformed the S&P 500 over the past 3 and 5 years despite a recent 1-year return of 12.42%.
Is Neurocrine Biosciences, Inc. overvalued or undervalued?
As of November 21, 2025, Neurocrine Biosciences, Inc. is considered an attractive investment due to its undervalued stock, strong fundamentals with a P/E ratio of 35, an EV to EBITDA of 21.72, and a robust ROCE of 30.61%, despite recent underperformance compared to the S&P 500.
Is Neurocrine Biosciences, Inc. technically bullish or bearish?
As of October 31, 2025, Neurocrine Biosciences, Inc. shows a bullish technical trend overall, supported by daily moving averages and monthly MACD, but with caution due to mixed signals from weekly indicators and underperformance against the S&P 500 in the longer term.
Is Neurocrine Biosciences, Inc. technically bullish or bearish?
As of October 31, 2025, Neurocrine Biosciences, Inc. shows a bullish trend overall, supported by daily moving averages and monthly MACD, but mixed signals from weekly indicators, while it has underperformed the S&P 500 with returns of 16.16% and 14.38% over the past year and three years, respectively.
Is Neurocrine Biosciences, Inc. technically bullish or bearish?
As of October 31, 2025, Neurocrine Biosciences, Inc. shows a bullish technical trend supported by daily moving averages and Bollinger Bands, despite mixed short-term signals from weekly indicators and underperformance compared to the S&P 500 over various time frames.
Is Neurocrine Biosciences, Inc. technically bullish or bearish?
As of October 31, 2025, Neurocrine Biosciences, Inc. shows a bullish technical trend overall, supported by daily moving averages and On-Balance Volume, but with caution due to mixed short-term signals and underperformance compared to the S&P 500.
Neurocrine Biosciences Experiences Revision in Stock Evaluation Amid Strong Market Performance
Neurocrine Biosciences, Inc. has recently experienced a revision in its evaluation amid fluctuating market conditions. The stock has demonstrated strong performance metrics, outpacing the S&P 500 over various time frames. Technical indicators show a predominantly bullish sentiment, although some mixed signals are present in the short term.
Is Neurocrine Biosciences, Inc. technically bullish or bearish?
As of October 24, 2025, Neurocrine Biosciences, Inc. shows a bullish trend with strong indicators, outperforming the S&P 500 recently, though it has underperformed over longer periods.
Is Neurocrine Biosciences, Inc. technically bullish or bearish?
As of October 24, 2025, Neurocrine Biosciences, Inc. has a bullish trend supported by strong indicators, although it has underperformed the S&P 500 over the longer term despite a recent weekly outperformance.
Is Neurocrine Biosciences, Inc. technically bullish or bearish?
As of October 24, 2025, Neurocrine Biosciences, Inc. has a bullish trend supported by strong indicators, although mixed signals from KST and Dow Theory suggest caution, while the stock has outperformed the S&P 500 in the short term but lags in longer periods.
Is Neurocrine Biosciences, Inc. overvalued or undervalued?
As of October 17, 2025, Neurocrine Biosciences, Inc. is considered overvalued with a valuation grade of expensive, reflected in its high P/E ratio of 35 and underperformance over five years compared to the S&P 500, despite a recent 18.26% return over the past year.
Neurocrine Biosciences Experiences Revision in Its Stock Evaluation Amid Strong Market Performance
Neurocrine Biosciences, Inc. has recently adjusted its valuation, with its current price at $140.09. The company has achieved an 18.26% return over the past year, outperforming the S&P 500. Key metrics indicate strong profitability and a premium valuation compared to industry peers, reflecting its competitive position.
Is Neurocrine Biosciences, Inc. overvalued or undervalued?
As of October 17, 2025, Neurocrine Biosciences, Inc. is considered overvalued with a valuation grade shift from fair to expensive, reflected by a high P/E ratio of 35 and mixed industry performance, despite a short-term stock return of 18.26% compared to the S&P 500's 14.08%.
Is Neurocrine Biosciences, Inc. overvalued or undervalued?
As of October 17, 2025, Neurocrine Biosciences, Inc. is considered overvalued with a valuation grade of expensive, reflected in its high P/E ratio of 35 and mixed performance compared to peers, despite a recent 1-year return of 18.26% that lags behind the S&P 500's longer-term returns.
Neurocrine Biosciences Experiences Revision in Stock Evaluation Amid Market Dynamics
Neurocrine Biosciences, Inc. has recently seen a stock price of $137.35, reflecting notable volatility over the past year. The company's performance has varied, with an 18.93% return compared to the S&P 500's 13.36%. Technical indicators present a mixed outlook, suggesting both bullish and bearish trends.
Is Neurocrine Biosciences, Inc. technically bullish or bearish?
As of October 10, 2025, Neurocrine Biosciences, Inc. shows a mildly bullish technical trend, supported by bullish MACD indicators and Bollinger Bands, despite mixed signals from the KST and recent underperformance against the S&P 500.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
